Category: Forbes

How CEO Martine Rothblatt Turns Moonshots Into Earthshots

At the Forbes Women’s Summit, United Therapeutics CEO Martine Rothblatt spoke about her ultimate goal of creating a never-ending supply of transplant organs, how her company became the largest pig cloner in the world, the moonshot she still wants to wo…

Steven Cohen Keeps Buying Acadia Pharmaceuticals, A Stock Down By Half This Year

The FDA said it would re-examine the company’s only drug sending shares tumbling

What’s Holding Back Market Uptake Of Biosimilars?

Four distinctly American features of the biosimilars market have limited uptake: A slow regulatory process, originator company behavior, lack of therapeutic interchangeability designation, and insufficient system-wide education efforts to overcome phys…

How A Reduction In Hospital Deaths Helped Amazon And Buffett Pick Atul Gawande

Amazon, Warren Buffett and JPMorgan Chase have picked noted surgeon and writer Dr. Atul Gawande to run their healthcare venture.

FindMeCure Does Exactly What It Says On The Tin

The equivalent of a Google for clinical trials, to make sense of the 250,00 listed, was what Maya Zlatanova realised she needed when she sought treatment for her sister.

A New Behavioral Therapy Helps Kids With Depression–And Their Parents

A behavioral intervention is effective in treating young kids with depression. It also helps their parents.

AMA To Trump: End ‘Inhumane’ Child Separation Border Policy

The American Medical Association urged theTrump administration to stop separating migrating children from their “parents or caregivers,” calling the ‘zero tolerance” policy “inhumane.”

There Go Those Drug Companies Inventing New Diseases Again

The biopharmaceutical industry isn’t perfect. But let’s stop with the nonsense that the industry invents diseases. It’s not true.

Lung Cancer’s Stigma Stymies Progress

The reality is that a stigma never tells the full story. And in the case of lung cancer, it doesn’t even come close.

AMA Says Regulators Should Block CVS-Aetna Deal

The American Medical Association said regulators should block the CVS-Aetna merger, saying it would lead to higher health costs and too much control over seniors’ Medicare drug plans.